Last reviewed · How we verify
NCT05429307
Turkish Adaptation, Validity and Reliability of Exercise Sensitivity Questionnaire
trial testing Population in Heart Diseases in 450 participants. Terminated before completion.
15 December 2022
Quick facts
| Lead sponsor | Reyhan Kaygusuz |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 450 |
| Start date | 1 May 2022 |
| Primary completion | 15 December 2022 |
| Estimated completion | 26 December 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Population
Conditions studied
- Heart Diseases — all drugs for Heart Diseases →
- Exercise Addiction — all drugs for Exercise Addiction →
- Sensitivity — all drugs for Sensitivity →
Sponsor
Reyhan Kaygusuz
Who can join
Adults 35 to 80, any sex, with Heart Diseases or Exercise Addiction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Interoceptive complex sensations and fear beliefs resulting from cardiac risk factors or cardiovascular disease can further increase one's awareness and attention to bodily situations and cause differences in the interpretation of somatic sensations. These intraceptive somatic sensations may be the underlying factors for participation in exercise and compliance with exercise programs No Turkish questionnaire evaluating unpleasant sensations (Exercise sensitivity) was found. Exercise Sensitivity Questionnaire, which we planned to validate in our study, is a questionnaire developed by Samantha Farris et al. in 2020 to measure anxiety, exercise avoidance behavior and exercise sensitivity, which are frequently observed in individuals with heart disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05429307
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Diseases
Currently open trials in the same condition.
- NCT07288216 — Transition to KPL-387 Monotherapy Dosing & Administration Study · Phase 2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
- NCT06954610 — Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation · recruiting
- NCT06769880 — Use of Bedside Imaging and Community Health Workers for Early Screening and Referral of Pre-symptomatic Stage B Heart Fa · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05429307 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Reyhan Kaygusuz
- Last refreshed: 2 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05429307.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing